Key result
Zacopride pretreatment at 15 μg/kg significantly reduced the incidence of ventricular fibrillation from 100% to 11.1% in a rat model of ischemia-reperfusion arrhythmias.
Why the study?
Inward rectifier potassium channels play critical roles in arrhythmogenesis, but how an IK1 agonist affects reperfusion arrhythmias and its underlying mechanisms needed clarification.
Does zacopride (an IK1 agonist) reduce reperfusion arrhythmias and intracellular calcium overload in rat models of ischemia/reperfusion?
Does zacopride (an IK1 agonist) reduce reperfusion arrhythmias and intracellular calcium overload in rat models of ischemia/reperfusion?
Absolute Event Rate: 11.1% vs 100%
p-value: p=<0.01
Zacopride, an IK1 agonist, effectively attenuates reperfusion-induced ventricular arrhythmias and calcium overload in rat models by modulating the CaMKII signaling pathway, suggesting a potential pharmacological target for ischemia-reperfusion injury.
Does not support clinical use in reperfusion arrhythmias; hypothesis-generating for IK1 agonism in ischemia-reperfusion models.
Inward rectifier potassium channels (IK1, Kir) are known to play critical roles in arrhythmogenesis. Thus, how IK1 agonist affects reperfusion arrhythmias needs to be clarified, and its underlying mechanisms should be determined. Reperfusion arrhythmias were modeled by coronary ligation (ischemia, 15 minutes) and release (reperfusion, 15 minutes). Zacopride (1.5-50 μg/kg in vivo, or 0.1-10 μmol/Lex vivo) was applied in the settings of pretreatment (3 minutes before coronary ligation) and posttreatment (5 minutes after coronary ligation). Hypoxia (45 minutes) /reoxygenation (30 minutes) model was established in cultured H9c2 (2-1) cardiomyocytes. Zacopride or KN93 was applied before hypoxia (pretreatment). In the setting of pre- or posttreatment, zacopride at 15 μg/kg in vivo or 1 μmol/Lin vitro exhibited superlative protections on reperfusion arrhythmias or intracellular calcium overload. Western blot data from ex vivo hearts or H9c2 (2-1) cardiomyocytes showed that I/R (H/R) induced the inhibition of Kir2.1 (the dominant subunit of IK1 channel in ventricle), phosphorylation and oxidation of CaMKII, downregulation of SERCA2, phosphorylation of phospholamban (at Thr17), and activation of caspase-3. Zacopride treatment (1 μmol/L) was noted to strikingly restore the expression of Kir2.1 and SERCA2 and decrease the activity of CaMKII, phospholamban, and caspase-3. These effects were largely eliminated by co-application of IK1 blocker BaCl2. CaMKII inhibitor KN93 attenuated calcium overload and p-PLB (Thr17) in an IK1-independent manner. IK1-depedent inhibition of CaMKII activity is found to be a key cardiac salvage signaling under Ca2+ dyshomeostasis and reactive oxygen species (ROS) stress. IK1 might be a novel target for pharmacological conditioning of reperfusion arrhythmia, especially for the application after unpredictable ischemia.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) studied Reperfusion arrhythmias. Zacopride vs. Ischemia/Reperfusion (I/R) model (normal saline) was evaluated on Incidence of ventricular fibrillation (VF) in vivo (p=<0.01). Zacopride pretreatment at 15 μg/kg significantly reduced the incidence of ventricular fibrillation from 100% to 11.1% in a rat model of ischemia-reperfusion arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: